Reuters logo
BRIEF-Savara expands molgradex development to include treatment of nontuberculous mycobacterial (NTM) lung infection
October 24, 2017 / 8:45 PM / in 24 days

BRIEF-Savara expands molgradex development to include treatment of nontuberculous mycobacterial (NTM) lung infection

Oct 24 (Reuters) - Savara Inc

* Savara announces expansion of molgradex development to include treatment of nontuberculous mycobacterial (NTM) lung infection

* Savara Inc - ‍company anticipates Phase 2A clinical trial will begin in early 2018​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below